Oncology Clinic
For decades, the Pediatric Oncology Clinic has been at the forefront of research and care for childhood cancer. We're among the first centers to offer new treatments as soon as they become available. With programs designed specifically for diagnosing and treating children, we're able to make the future brighter for many of the patients who come to us for care.
Our team of world-renowned experts cares for patients with every type of childhood cancer. That compassionate medical care is complemented by a wide range of services designed to support our patients' well-being throughout their treatment course. We understand that undergoing cancer treatment is emotionally difficult, and we offer not just a helping hand but a hand to hold.
In addition to treating patients, our doctors lead world-class research aimed at advancing the understanding and treatment of cancer. Thanks to that work, our patients often have opportunities to participate in large-scale clinical trials of promising experimental drugs or other therapies.
Our overarching goal is to help kids get better as quickly as possible so they can put cancer behind them and get on with their lives.
Our locations (3)
Highlights of our cancer care
Leading-edge treatments
We're among the first to offer new treatment options, as soon as they're proven safe and effective. In addition, patients can access promising experimental therapies by participating in one of our many clinical trials.
Precision medicine
High-risk tumors are analyzed with the UCSF500 Cancer Gene Panel, a state-of-the-art test that identifies mutations in the tumor's DNA. The results can indicate the best treatment course and, in some cases, clarify the exact type of cancer.
Seamless care, near and far
Dedicated patient navigators help families with managing referrals, insurance concerns and appointment planning. We work with patients and referring doctors well beyond the San Francisco Bay Area, thanks to our comprehensive telehealth system.
Thorough follow-up
Our Pediatric Survivorship Program provides expert care to address any medical, psychological or social issues that arise after treatment is complete. The team also ensures smooth transitions to adult care providers as our patients leave childhood behind.
Our team
-
Katherine K. Matthay
MD
Pediatric hematologist-oncologist -
Anurag K. Agrawal
MD
Pediatric hematologist-oncologist -
Anuradha Banerjee
MD, MPH
Pediatric neuro-oncologist -
Barbara Beach
MD
Pediatric hematologist-oncologist -
Benjamin S. Braun
MD, PhD
Pediatric hematologist-oncologist -
Maria I. Castellanos
MD
Pediatric hematologist-oncologist -
Robert E. Goldsby
MD
Pediatric hematologist-oncologist -
Carla Golden
MD
Pediatric hematologist-oncologist -
W. Clay Gustafson
MD
Pediatric hematologist-oncologist -
Caroline Hastings
MD
Hematologist-oncologist and neuro-oncologist -
Michelle L. Hermiston
MD, PhD
Pediatric hematologist-oncologist -
Benjamin J. Huang
MD
Pediatric hematologist-oncologist -
Marie Jaeger-Krause
MD
Pediatric hematologist-oncologist and neuro-oncologist -
Rohini Jain
MD
Pediatric hematologist-oncologist -
Anya Levinson
MD
Pediatric hematologist-oncologist -
Amanda Marinoff
MD
Pediatric hematologist-oncologist -
Jennifer Michlitsch
MD
Pediatric hematologist-oncologist -
Sabine Mueller
MD, PhD, MAS
Pediatric neurologist and neuro-oncologist -
Brian S. Na
MD
Neuro-oncologist -
Cheryl Peretz
MD
Pediatric hematologist-oncologist -
Bo Qiu
MD, PhD
Pediatric oncologist -
Robert Raphael
MD
Pediatric hematologist-oncologist -
Alyssa Reddy
MD
Pediatric neurologist and neuro-oncologist -
Elizabeth Robbins
MD
Pediatric hematologist-oncologist -
Amit J. Sabnis
MD, MS
Pediatric hematologist-oncologist -
Elizabeth Seashore
MD
Pediatric hematologist-oncologist and palliative care physician -
Alejandro Sweet-Cordero
MD
Pediatric hematologist-oncologist -
Mark Walters
MD
Pediatric hematologist-oncologist -
Natalie Wu
MD, MS
Pediatric hematologist-oncologist -
Elizabeth (Betsy) Young
MD
Pediatric hematologist-oncologist -
Kathryn Aaronson
NP
Nurse practitioner -
Judy Cavazos
PhD
Psychologist -
Jenny Chen
MS
Dietitian -
Lea Fox
NP
Nurse practitioner -
Carly Hoffman
PNP, MSN
Pediatric nurse practitioner -
Fabienne Hollinger
FNP, MSN
Family nurse practitioner -
Yennie Lo
RD
Dietitian -
Jennifer S. Murphy
PNP, MSN
Nurse practitioner -
Makiko Omori
RD
Dietitian -
Anthony Ong
DPT
Physical therapist -
Kathleen Praxedes
LCSW
Social worker -
Shannon H. Raber
PNP, MSN
Pediatric nurse practitioner -
Erica Southworth
PNP, MSN
Pediatric nurse practitioner -
Sarah Schleimer
PNP, MSN
Pediatric nurse practitioner -
Kristen Steglich
LCSW
Social worker -
Molly Szuminski
NP, MSN
Nurse practitioner
-
Katherine K. Matthay
MD
Pediatric hematologist-oncologist -
Anurag K. Agrawal
MD
Pediatric hematologist-oncologist -
Anuradha Banerjee
MD, MPH
Pediatric neuro-oncologist -
Barbara Beach
MD
Pediatric hematologist-oncologist -
Benjamin S. Braun
MD, PhD
Pediatric hematologist-oncologist -
Maria I. Castellanos
MD
Pediatric hematologist-oncologist -
Robert E. Goldsby
MD
Pediatric hematologist-oncologist -
Carla Golden
MD
Pediatric hematologist-oncologist -
W. Clay Gustafson
MD
Pediatric hematologist-oncologist -
Caroline Hastings
MD
Hematologist-oncologist and neuro-oncologist -
Michelle L. Hermiston
MD, PhD
Pediatric hematologist-oncologist -
Benjamin J. Huang
MD
Pediatric hematologist-oncologist -
Marie Jaeger-Krause
MD
Pediatric hematologist-oncologist and neuro-oncologist -
Rohini Jain
MD
Pediatric hematologist-oncologist -
Anya Levinson
MD
Pediatric hematologist-oncologist -
Amanda Marinoff
MD
Pediatric hematologist-oncologist -
Jennifer Michlitsch
MD
Pediatric hematologist-oncologist -
Sabine Mueller
MD, PhD, MAS
Pediatric neurologist and neuro-oncologist -
Brian S. Na
MD
Neuro-oncologist -
Cheryl Peretz
MD
Pediatric hematologist-oncologist -
Bo Qiu
MD, PhD
Pediatric oncologist -
Robert Raphael
MD
Pediatric hematologist-oncologist -
Alyssa Reddy
MD
Pediatric neurologist and neuro-oncologist -
Elizabeth Robbins
MD
Pediatric hematologist-oncologist -
Amit J. Sabnis
MD, MS
Pediatric hematologist-oncologist -
Elizabeth Seashore
MD
Pediatric hematologist-oncologist and palliative care physician -
Alejandro Sweet-Cordero
MD
Pediatric hematologist-oncologist -
Mark Walters
MD
Pediatric hematologist-oncologist -
Natalie Wu
MD, MS
Pediatric hematologist-oncologist -
Elizabeth (Betsy) Young
MD
Pediatric hematologist-oncologist
-
Kathryn Aaronson
NP
Nurse practitioner -
Lea Fox
NP
Nurse practitioner -
Carly Hoffman
PNP, MSN
Pediatric nurse practitioner -
Fabienne Hollinger
FNP, MSN
Family nurse practitioner -
Jennifer S. Murphy
PNP, MSN
Nurse practitioner -
Shannon H. Raber
PNP, MSN
Pediatric nurse practitioner -
Sarah Schleimer
PNP, MSN
Pediatric nurse practitioner -
Erica Southworth
PNP, MSN
Pediatric nurse practitioner -
Molly Szuminski
NP, MSN
Nurse practitioner
Awards & recognition
-
Best in Northern California for cancer care
-
Ranked among the nation's best in 11 specialties
-
Designated an early phase clinical trials core site by the Children's Oncology Group
UCSF's Pediatric Cancer Program
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your child's condition
- List of medications, including dosages, plus any your child is allergic to
- List of questions you may have
- Device or paper for taking notes
- Completed medical forms that we will mail to you ahead of time
Related clinics (6)
Blood & Marrow Transplant (BMT) Clinic
Hematology Clinic
Pediatric Hereditary Cancer Clinic
Support services
Clinical trials
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
To measure the response of treatments chosen based on: • Event free survival (EFS)
Recruiting
More about this studyEflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
To evaluate the efficacy of difluoromethylornithine (DFMO) in combination with etoposide in patients with relapsed/refractory neuroblastoma, based upon: o Event free survival (EFS) from time of enrollment.
Recruiting
More about this studyNaxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Measured by the presence of radiologically assessable disease by cross-sectional computed tomography (CT) or Magnetic resonance imaging (MRI) imaging and/or by metaiodobenzylguanidine (MIBG) or positron emission tomography (PET) s...
Recruiting
More about this studyCaloric Restriction and Activity to Reduce Chemoresistance in B-ALL
To compare the rate of MRD >=0.01% at end of induction between experimental arm and control arm
Recruiting
More about this studyProject: Every Child for Younger Patients With Cancer
The number of patients who agree to be in the Biobanking part of the study and have leftover tumor tissue and some normal blood, bone marrow, or other tissue saved for future research.
Recruiting
More about this studyChemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusi...
The Kaplan-Meier method will be used to estimate 3-year FFS along with 80% log-minus-log transformed confidence limits for very low risk (VLR) patients.
Recruiting
More about this studyInotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...
Improvement in 5-year disease-free survival (DFS) with modified Berlin-Frankfurt-Münster (mBFM) chemotherapy without delayed intensification (DI) part 2 but with inotuzumab ozogamicin, versus full mBFM chemotherapy backbone includ...
Recruiting
More about this studyA Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Seve...
The median time to failure or death will be compared on the two arms using the log-rank test. Failure of IST is defined as the date that a second definitive therapy was recommended (BMT, second course of ATG) and failure of BMT de...
Recruiting
More about this studyDinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Child...
EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred.
Recruiting
More about this studyOur research initiatives
Staff superheroes